このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Xeris Biopharma Holdings マネジメント

マネジメント基準チェック /24

Xeris Biopharma Holdings'の CEO はPaul Edickで、 May2021年に任命され、の在任期間は 3.08年です。の年間総報酬は$ 2.14Mで、 32.5%給与と67.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.78%を直接所有しており、その価値は$ 2.56M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と2.7年です。

主要情報

Paul Edick

最高経営責任者

US$2.1m

報酬総額

CEO給与比率	32.5%
CEO在任期間	3.1yrs
CEOの所有権	0.8%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

CEO報酬分析

Xeris Biopharma Holdings の収益と比較して、Paul Edick の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$64m
Dec 31 2023	US$2m	US$694k	-US$62m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$78m
Dec 31 2022	US$3m	US$692k	-US$95m
Sep 30 2022	n/a	n/a	-US$133m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$138m
Dec 31 2021	US$4m	US$664k	-US$123m
Sep 30 2021	n/a	n/a	-US$94m
Jun 30 2021	n/a	n/a	-US$84m
Mar 31 2021	n/a	n/a	-US$80m
Dec 31 2020	US$2m	US$627k	-US$91m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$119m
Mar 31 2020	n/a	n/a	-US$129m
Dec 31 2019	US$4m	US$598k	-US$126m
Sep 30 2019	n/a	n/a	-US$113m
Jun 30 2019	n/a	n/a	-US$95m
Mar 31 2019	n/a	n/a	-US$73m
Dec 31 2018	US$1m	US$535k	-US$60m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$42m
Mar 31 2018	n/a	n/a	-US$34m
Dec 31 2017	US$1m	US$490k	-US$27m

報酬と市場: Paulの総報酬 ($USD 2.14M ) は、 US市場 ($USD 2.45M ) の同様の規模の企業の平均とほぼ同じです。

CEO（最高経営責任者

Paul Edick (68 yo)

3.1yrs

在職期間

US$2,136,766

報酬

Mr. Paul R. Edick serves as the Chief Executive Officer of Xeris Biopharma Holdings, Inc. since May 2021 in connection with the Strongbridge acquisition and has been its Chairman since 2021. He served as P...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Edick	Chairman & CEO	3.1yrs	US$2.14m	0.78% $ 2.5m
John Shannon	President & COO	2.7yrs	US$1.85m	0.37% $ 1.2m
Steven Pieper	Chief Financial Officer	2.7yrs	US$1.61m	0.26% $ 843.9k
Beth Hecht	Chief Legal Officer & Corporate Secretary	2.7yrs	US$1.13m	0.21% $ 689.2k
Kenneth Johnson	Senior VP of Global Development & Medical Affairs	2.7yrs	US$720.97k	0.071% $ 229.5k
Allison Wey	Senior Vice President of Investor Relations & Corporate Communications	5.9yrs	データなし	データなし
Kevin McCulloch	Chief Commercial Officer	no data	データなし	データなし

2.7yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: XERSの経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Edick	Chairman & CEO	3.4yrs	US$2.14m	0.78% $ 2.5m
John Brooks	Scientific Advisory Board Member	no data	データなし	データなし
Orville Kolterman	Member of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Sherman	Independent Director	2.7yrs	US$175.75k	0.081% $ 261.1k
John Schmid	Lead Independent Director	2.7yrs	US$218.25k	0.054% $ 173.4k
Garheng Kong	Independent Non-Executive Director	2.7yrs	US$173.25k	0.077% $ 248.8k
W. Ward	Member of Scientific Advisory Board	no data	データなし	データなし
Marla Persky	Independent Director	2.7yrs	US$183.25k	0.043% $ 139.2k
Morey Haymond	Scientific Advisory Board Member	no data	データなし	データなし
John Johnson	Independent Non-Executive Director	2.7yrs	US$168.25k	0.57% $ 1.8m
Barbar-Jean Bormann-Kennedy	Independent Director	2.7yrs	US$183.25k	0.039% $ 125.3k
Dawn Halkuff	Independent Director	2.7yrs	US$175.75k	0.042% $ 137.1k

2.7yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: XERSの取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Xeris Biopharma Holdings マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Xeris Biopharma Holdings, Inc., Annual General Meeting, Jun 05, 2024

Independent Non-Executive Director exercised options to buy US$472k worth of stock.

President & COO recently bought US$50k worth of stock

High number of new and inexperienced directors

Chairman & CEO recently bought US$140k worth of stock

Less than half of directors are independent

Recent updates

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.12 loss in 1Q 2023)

Xeris Biopharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Xeris Biopharma Holdings, Inc., Annual General Meeting, Jun 05, 2024

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Independent Non-Executive Director exercised options to buy US$472k worth of stock.

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Full year 2023 earnings: EPS misses analyst expectations

Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Forecast to breakeven in 2026

President & COO recently bought US$50k worth of stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xeris Biopharma Holdings, Inc. Revises Revenue Guidance for the Full Year 2023

Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2023

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Xeris Biopharma Holdings, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Xeris Biopharma Holdings, Inc. Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Consensus estimates of losses per share improve by 19%

Forecast to breakeven in 2025

Xeris Biopharma Holdings, Inc. Affirms Earnings Guidance for 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 9.1% to US$5.00

Xeris Biopharma Holdings, Inc. Updates Product Revenue Guidance for the Full Year 2022

Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xeris Biopharma Holdings, Inc. Provides Product Revenue Guidance for the Full Year 2022

Xeris Biopharma Holdings, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Xeris Biopharma Holdings, Inc. Announces Results of the Extended Evaluation of Recorlev (Levoketoconazole) from the Phase 3 Sonics Study Published in the European Journal of Endocrinology

Second quarter 2022 earnings: EPS exceeds analyst expectations

Xeris Biopharma Holdings, Inc. Reaffirms Revenue for the Full Year 2022

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Xeris Biopharma Holdings, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Arecor Therapeutics plc (AIM:AREC) agreed to acquire Tetris Pharma Limited from Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS).

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

Chairman & CEO recently bought US$140k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Xeris Announces Full Results from the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data At AACE Annual Meeting May 12-14

Xeris Biopharma Holdings, Inc. Affirms Revenue Guidance for the Year 2022

Xeris Biopharma Holdings, Inc. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

Consensus EPS estimates fall by 56%

No longer forecast to breakeven

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Xeris Biopharma Holdings, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Xeris Continues To Execute And Build Long-Term Value Potential

Xeris Biopharma Holdings, Inc. Announces Recorlev Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing’S Syndrome

Xeris Biopharma Holdings, Inc. announced that it expects to receive $30 million in funding from Armistice Capital LLC

Forecast to breakeven in 2024

Xeris Biopharma Announces U.S. FDA Approval of Recorlev (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Xeris Biopharma Holdings, Inc Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

Chairman & CEO recently bought US$416k worth of stock

Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.35 loss in 3Q 2020)

Independent Non-Executive Board Member Marla Persky has left the company

Independent Non-Executive Board Member Dawn Halkuff has left the company

Independent Non-Executive Board Member Barbar-Jean Bormann-Kennedy has left the company

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /24